Major histocompatibility complex class I–T-cell receptor complex (MHC I–TCR complex)

The Major histocompatibility complex class I–T-cell receptor complex (MHC I–TCR complex) is a cell-surface molecular complex fundamental for adaptive immunity. It consists of an MHC class I molecule (expressed on almost all nucleated cells) presenting an intracellularly derived peptide, which is specifically recognized by the T-cell receptor (TCR) often on a cytotoxic (CD8+) T cell. The TCR binds to the MHC I–peptide complex with high specificity, typically requiring coreceptor CD8 for stabilization and efficient signal transduction[1][3][5][6][7]. This recognition event is the primary activation step leading to cytotoxic T-cell effector functions, including the targeted killing of infected or malignant cells. The structure and function of the complex are central to immune-mediated diseases, tumor immunology, and the effects of various immunotherapies[1][3][6]. Additional details: - Is_incorrect = true because "MHC I / T-cell Receptor complex" is not the official canonical name for a gene, protein, or single molecule; instead, it is a multiprotein complex describing the interaction between an MHC class I molecule (HLA-A/B/C in humans) and the T-cell receptor (TCR) on cytotoxic T cells. These are typically listed as separate targets in drug and biomarker databases. - Aliases include variations referencing the ternary interaction but no widely accepted abbreviation beyond "MHC I–TCR". - Interacting drugs act indirectly at this interface; there are no small molecules/drugs that directly bind both MHC I and TCR simultaneously, but many drugs modulate this pathway[6]. If you need information on the individual components (“Major histocompatibility complex class I” or “T-cell receptor”), they are considered distinct protein targets. The description here is specific to their complex and immunological synapse.

Other names

MHC class I–TCR complexMHC-I–TCRpeptide–MHC I–TCRMHC I/peptide–TCR

Blockade of TCR signaling (via immunosuppressants); Enhancement of T-cell activation/anti-tumor immunity (via checkpoint inhibition)